AVXL
Anavex Life Sciences Corp
NASDAQ · Biotechnology
$4.10
+0.29 (+7.61%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 62.53M | 56.87M | 56.55M |
| Net Income | 10.24M | 9.50M | 10.72M |
| EPS | — | — | — |
| Profit Margin | 16.4% | 16.7% | 19.0% |
| Rev Growth | +23.0% | -7.3% | -7.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 148.71M | 159.64M | 129.30M |
| Total Equity | 185.46M | 160.49M | 169.59M |
| D/E Ratio | 0.80 | 0.99 | 0.76 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 18.97M | 15.63M | 16.61M |
| Free Cash Flow | 7.70M | 5.60M | 6.46M |